Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.
Anti-Inflammatory Agents
/ therapeutic use
Betacoronavirus
COVID-19
Colchicine
/ therapeutic use
Comorbidity
Coronavirus Infections
/ drug therapy
Duration of Therapy
Glucocorticoids
/ therapeutic use
Humans
Inflammation
/ drug therapy
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Pandemics
Pericarditis
/ drug therapy
Pneumonia, Viral
/ drug therapy
Receptors, Interleukin-1
/ antagonists & inhibitors
SARS-CoV-2
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
14
7
2020
medline:
13
8
2020
entrez:
14
7
2020
Statut:
ppublish
Résumé
: The COVID-19 pandemic is challenging our cardiovascular care of patients with heart diseases. In the setting of pericardial diseases, there are two possible different scenarios to consider: the patient being treated for pericarditis who subsequently becomes infected with SARS-CoV-2, and the patient with COVID-19 who develops pericarditis or pericardial effusion. In both conditions, clinicians may be doubtful regarding the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, and biological agents, such as anti-IL1 agents (e.g. anakinra), that are the mainstay of therapy for pericarditis.For NSAIDs, there is no clear scientific evidence linking ibuprofen and other NSAIDs to worsening of COVID-19; however, it seems prudent to continue them, if necessary to control pericarditis, and on the other hand, to prefer paracetamol for fever and systemic symptoms related to COVID-19. Treatments with corticosteroids, colchicine, and anakinra appear well tolerated in the context of COVID-19 infection and are currently actively evaluated as potential therapeutic options for COVID infection at different stages of the disease. On this basis, currently most treatments for pericarditis do not appear contraindicated also in the presence of possible COVID-19 infection and should not be discontinued, and some (corticosteroids, colchicine, and anakinra) can be considered to treat both conditions.
Identifiants
pubmed: 32658005
doi: 10.2459/JCM.0000000000001059
pii: 01244665-202009000-00001
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Glucocorticoids
0
Interleukin 1 Receptor Antagonist Protein
0
Receptors, Interleukin-1
0
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-629Références
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062.
Adler Y, Charron P, Imazio M, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921–2964.
Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial. JAMA 2016; 316:1906–1912.
Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol 2019; 27:956–964.
Imazio M, Brucato A, Cemin R, et al. ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013; 369:1522–1528.
Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014; 383:2232–2237.
Bayes-Genis A, Adler Y, de Luna AB, Imazio M. Colchicine in pericarditis. Eur Heart J 2017; 38:1706–1709.
Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB. Cardiac tamponade secondary to COVID-19. JACC Case Rep 2020; [Epub ahead of print].
Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J 2020; ehaa253[Epub ahead of print].
Marschall A, Concepción Suárez R, Dejuan Bitriá C, Fernández Pascual MC. Acute pericarditis secondary to COVID-19. Pericarditis aguda secundaria a COVID-19. Emergencias 2020; 32:221–222.
Cizgici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myopericarditis: it should be kept in mind in today's conditions. Am J Emerg Med 2020; S0735-6757:30310–30317.
Imazio M, Adler Y. Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev 2013; 18:355–360.
Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown) 2016; 17:263–269.
Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 2011; 147:477–478.
Little P. Nonsteroidal anti-inflammatory drugs and covid-19. BMJ 2020; 368:m1185.
Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ 2020; 368:m1168.
WHO Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance. 13 March 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acuterespiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. [Accessed June 2, 2020].
Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel Covid-19 – a systematic review of current evidence. ecancer 2020; 14:1022.
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020; ehaa190[Epub ahead of print].
Irabien-Ortiz Á, Carreras-Mora J, Sionis A, Pàmies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol (Engl Ed) 2020; S1885-5857:30165–30171.
Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; [Epub ahead of print].
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 105955: [Epub ahead of print].
Hasan K, Siddiqi MD, Mandeep MSCR, Mehra R, MSc MD. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39:405–407.
Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des 2018; 24:659–663.
Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018; 269:262–271.
Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol 2016; 68:2311–2328.
Richter M, Boldescu V, Graf D, et al. Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-activated prodrugs as antiviral agents. ChemMedChem 2019; 14:469–483.
Biswas K, Das Sarma J. Effect of microtubule disruption on neuronal spread and replication of demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro. J Virol 2014; 88:3043–3079.
Lu N, Yang Y, Liu H, et al. Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine. Biotech 2019; 9:392.
Milewska A, Nowak P, Owczarek K, et al. Entry of human coronavirus NL63 into the cell. J Virol 2018; 92:e01933–e02017.
Worachartcheewan A, Songtawee N, Siriwong S, Prachayasittikul S, Nantasenamat C, Prachayasittikul V. Rational design of colchicine derivatives as anti-HIV agents via QSAR and molecular docking. Med Chem 2019; 15:328–340.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–1034.
Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-center cohort of adult hospitalized patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020; in press.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016; 44:275–281.
Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc 2020; [Epub ahead of print].
Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020.